Immunology. Considering therapeutic antibodies.
Vitetta
Ellen S
ES
Cancer Immunobiology Center, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75235-8576, USA. ellen.vitetta@utsouthwestern.edu
Ghetie
Victor F
VF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000915:Antibody Affinity; D001666:Binding Sites, Antibody; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016207:Cytokines / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D006207:Half-Life; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology; D007074:Immunoglobulin G / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D007167:Immunotherapy; D008213:Lymphocyte Activation; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D015202:Protein Engineering; D013601:T-Lymphocytes / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; C509303:TGN-1412